(ENCORE) Rinatabart sesutecan for patients with advanced ovarian cancer: Results from dose expansion cohort B1 of phase I/II study

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2025-09-01 DOI:10.1016/j.ygyno.2025.03.100

Elizabeth Lee , Oladapo Yeku , Ira Winer , Erika Hamilton , Debra Richardson , Jian Zhang , Gottfried Konecny , Ian Anderson , Xiaohua Wu , Douglass Orr , Sandip Patel , Andrea Jewell , Jing Wang , Alexander Spira , Anton Melnyk , Leigh Seamon , Ibrahima Soumaoro , Edward Kavalerchik , Zhu Chen , Michael Gillespie , Justin Call

引用次数: 0

查看原文本刊更多论文

（ENCORE）瑞那他巴塞舒替康用于晚期卵巢癌患者：来自I/II期研究剂量扩展队列B1的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy